Investigator Supported Trials

Nektar Therapeutics (Nektar) has a deep and diverse portfolio of investigational medicine products (IMP)s in different stages of clinical development. Our team of dedicated scientists, clinicians and employees are focused on bringing new medicines to patients with debilitating diseases.

As a research-based biopharmaceutical company, Nektar conducts preclinical and clinical studies of our IMPs to evaluate them for both safety and efficacy through company sponsored as well as independently sponsored studies and trials such as Investigator Sponsored Trials (IST).

ISTs are independent research conducted by external investigators and can advance the medical and scientific knowledge of IMPs. Research conducted through an IST can provide valuable information regarding the safety, efficacy, pharmacology, and tolerability of Nektar's IMPs. Nektar may provide support for an IST based upon the following guidance:

  • IST proposals must be unsolicited and relate to original research that aligns with, and does not conflict with, Nektar’s ongoing research and development plans.
  • Nektar does not support any proposal that induces or is intended to induce the use, administration or recommendation of Nektar products by the investigator or other Healthcare Professionals (HCP).
  • Decisions regarding support for IST (whether financial and/or provision of study drug) must be made based upon safety and acceptable and appropriate risk/benefit profile for patients, scientific merit of the proposed project, clinical usefulness of the data expected to be generated, and other objective criteria.

If you are interested in more information, please contact medicalaffairs@nektar.com